Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aurinia Pharm Ord (AUPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 458,726
  • Shares Outstanding, K 84,480
  • Annual Sales, $ 420 K
  • Annual Income, $ -70,790 K
  • 36-Month Beta 2.18
  • Price/Sales 1,092.18
  • Price/Cash Flow N/A
  • Price/Book 3.23

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.18
  • Number of Estimates 4
  • High Estimate -0.14
  • Low Estimate -0.19
  • Prior Year -0.16
  • Growth Rate Est. (year over year) -12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.22 +1.92%
on 08/07/18
5.98 -11.04%
on 07/24/18
-0.35 (-6.17%)
since 07/17/18
3-Month
5.22 +1.92%
on 08/07/18
6.35 -16.22%
on 06/18/18
-0.79 (-12.93%)
since 05/17/18
52-Week
4.41 +20.63%
on 12/19/17
7.60 -30.00%
on 10/13/17
-0.79 (-12.93%)
since 08/17/17

Most Recent Stories

More News
Investor Expectations to Drive Momentum within Natural Resource Partners LP, Insmed, MagnaChip Semiconductor, Changyou, Pain Therapeutics, and Aurinia Pharmaceuticals -- Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Natural Resource Partners LP...

AUPH : 5.32 (-2.03%)
CYOU : 13.76 (-0.65%)
PTIE : 0.92 (-10.68%)
MX : 11.30 (-0.88%)
NRP : 31.70 (+0.48%)
INSM : 20.99 (+0.33%)
Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of -18.75% and 447.17%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

AUPH : 5.32 (-2.03%)
Aurinia Reports Second Quarter Financial Results and Operational Highlights

--Trials in FSGS and Dry Eye initiated

AUP.TO : 6.98 (-2.38%)
AUPH : 5.32 (-2.03%)
Today's Research Reports on Cipher Pharmaceuticals, Aurinia Pharmaceuticals, GeneNews and Neovasc

NEW YORK, NY / ACCESSWIRE / July 30, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register...

AUPH : 5.32 (-2.03%)
CPH.TO : 2.94 (+3.89%)
Aurinia Initiates Phase 2 Clinical Trial for Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX: AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the initiation of its Phase 2 trial...

AUP.TO : 6.98 (-2.38%)
AUPH : 5.32 (-2.03%)
Aurinia Initiates Clinical Trials Broadening the Development of Voclosporin

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the enrollment of the first patients...

AUP.TO : 6.98 (-2.38%)
AUPH : 5.32 (-2.03%)
Aurinia Announces Results of Annual General Meeting

Aurinia Pharmaceuticals Inc. ("Aurinia" or the "Company") (NASDAQ: AUPH / TSX: AUP) is pleased to announce that the eight incumbent directors of the Company were elected at the Company's...

AUP.TO : 6.98 (-2.38%)
AUPH : 5.32 (-2.03%)
Today's Research Reports on Hemostemix, Cotinga Pharmaceuticals, Aurinia Pharmaceuticals and Baylin Technologies

NEW YORK, NY / ACCESSWIRE / June 22, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register...

AUPH : 5.32 (-2.03%)
Today's Free Reports Concordia International, ProMetic Life Sciences, Aurinia Pharma, and Oncolytics Biotech

LONDON, UK / ACCESSWIRE / June 20, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: Concordia International, ProMetic...

AUPH : 5.32 (-2.03%)
PFSCF : 0.4800 (-2.04%)
CXR.TO : 0.24 (unch)
Factors of Influence in 2018, Key Indicators and Opportunity within Shinhan Financial Group, Aurinia Pharmaceuticals, Delphi Technologies, Green Plains Partners LP, Sprague Resources LP, and CRH -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Shinhan Financial Group Co...

DLPH : 39.43 (-0.25%)
AUPH : 5.32 (-2.03%)
SHG : 38.02 (+1.01%)
SRLP : 24.80 (+1.22%)
GPP : 15.55 (-0.96%)
CRH : 32.51 (+1.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

See More Share

Trade AUPH with:

Business Summary

Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

See More

Key Turning Points

2nd Resistance Point 5.54
1st Resistance Point 5.43
Last Price 5.32
1st Support Level 5.23
2nd Support Level 5.14

See More

52-Week High 7.60
Fibonacci 61.8% 6.38
Fibonacci 50% 6.01
Fibonacci 38.2% 5.63
Last Price 5.32
52-Week Low 4.41

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar